Why the study?
Does antecedent aspirin use for primary prevention reduce infarct size in patients with de novo acute myocardial infarction?
Does antecedent aspirin use for primary prevention reduce infarct size in patients with de novo acute myocardial infarction?
Antecedent aspirin use for primary prevention is associated with smaller infarct size without an increased risk of bleeding in patients presenting with de novo acute myocardial infarction.
Should not change primary prevention practice; hypothesis-generating for infarct size effects and requires prospective confirmation.
Patients with de novo acute myocardial infarction using aspirin for primary prevention have an unexpectedly smaller infarct size and similar bleeding rates.
No takes yet. Share an insight, caveat, or question.
Enhoş et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: